Previous close | 125.79 |
Open | 126.15 |
Bid | 127.75 x 1200 |
Ask | 127.76 x 1100 |
Day's range | 125.99 - 127.89 |
52-week range | 75.56 - 138.28 |
Volume | |
Avg. volume | 5,016,329 |
Market cap | 570.247B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 47.87 |
EPS (TTM) | 2.67 |
Earnings date | N/A |
Forward dividend & yield | 1.37 (1.09%) |
Ex-dividend date | 22 Mar 2024 |
1y target est | 144.83 |
Earnings preview of key companies reporting next week and what to look out for.
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?